NCT06611930 - CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

November 18, 2025

Study Completion Date

January 7, 2026

Conditions

Type 2 Diabetes Mellitus (T2DM)Obesity and Overweight

Interventions

DRUG

CK-0045

Interleukin-22 agonist

DRUG

Placebo

Placebo (liquid for injection, which includes no active ingredient).

Trial Locations (2)

CRS Clinical Reserach Services Mannheim GmbH, Mannheim

Profil Institut für Stoffwechselforschung GmbH, Neuss